Yu, Evan Y.
Ellard, Susan L.
Hotte, Sebastien J.
Gingerich, Joel R.
Joshua, Anthony M.
Gleave, Martin E.
Chi, Kim N.
Funding for this research was provided by:
Terry Fox Research Institute (2008-11)
OncoGeneX Pharmaceuticals, Inc.
Article History
Received: 20 November 2017
Accepted: 12 December 2017
First Online: 18 December 2017
Compliance with ethical standards
:
: The institution of EYY received funding from OncoGeneX Pharmaceuticals, Inc. to aid in performance of the submitted research. The University of British Columbia has licensed patent applications on OGX-427, listing MEG as inventor, to OncoGenex Technologies, a Vancouver-based biotechnology company that MEG has founding shares in. Otherwise, there are no conflicts of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.